Roper Industries, Inc. — Q1 2014 Form 10-Q
Business context and period. The filing covers the three months ended March 31, 2014, compared with Q1 2013. Roper reported four segments: Industrial Technology, Energy Systems & Controls, Medical & Scientific Imaging, and RF Technology. The filing identifies the registrant as Roper Industries, Inc.
Financial performance
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Net sales | $834.1 million | $737.1 million |
| Gross profit / margin | $488.9 million / 58.6% | $421.6 million / 57.2% |
| Operating income | $223.4 million | $185.2 million |
| Net earnings | $147.2 million | $124.9 million |
| Diluted EPS | $1.46 | $1.25 |
| Operating cash flow | $212.6 million | $171.3 million |
- Sales increased 13%: 8% organic growth and 5% contribution from 2013 acquisitions. Net earnings rose about 18%; diluted EPS rose about 17%.
- Consolidated operating margin, including corporate expenses, was 26.8%, versus 25.1%. Segment operating profit was $245.4 million, before $22.0 million of corporate expenses.
- Net orders were $846.5 million, up 7%; backlog was $1.064 billion, up 7% year over year.
- Operating cash flow increased 24%. Investing used $12.5 million, primarily for capital expenditures; financing used $154.6 million, primarily for debt repayments and dividends. Cash increased to $502.9 million.
- Total debt was $2.315 billion, down from $2.465 billion at year-end 2013. Net debt was $1.812 billion, and net debt to total net capital declined to 29.4% from 32.3%. The company had $100 million drawn on its $1.5 billion revolving facility and reported compliance with debt covenants.
- Current assets were $1.432 billion and current liabilities were $668.0 million. Net working capital, as defined by the company, was $272 million versus $282 million at December 31, 2013.
Material changes and management commentary
- Medical & Scientific Imaging led segment growth: sales rose 28% (9% organic; 19% acquisitions), and operating margin increased to 35.0% from 29.9%, with higher-margin medical products and software cited as a benefit.
- Industrial Technology sales grew 8%, but margin declined to 28.5% from 29.1%, primarily due to product mix. Energy Systems & Controls sales rose 7%; margin eased to 23.9% from 24.5%, with acquisition integration costs cited. RF Technology sales increased 8%, and margin improved to 27.7% from 27.1%.
- The effective tax rate was 28.2%, versus 22.8% in Q1 2013. The current quarter included a $6 million reduction in unrecognized tax-benefit liabilities from statute expiration; the prior-year rate benefited from discrete tax items. Management expected a roughly 31% effective tax rate for full-year 2014.
- Interest expense fell to $19.8 million from $20.9 million, attributed to lower average rates despite higher average debt balances. Other income was $1.4 million versus $2.5 million of other expense, mainly reflecting foreign-exchange gains and losses at non-U.S. subsidiaries.
- Foreign-currency translation reduced comprehensive income by $12.8 million. Management said $8 million of the quarter’s foreign-exchange impact related to goodwill and did not directly affect expected cash flows.
Outlook, risks, and contingencies
- Management expected operating cash flows to support debt reduction, but noted that the pace would depend on operating performance and acquisition financing needs. It said available cash, U.S. operating cash flow, credit facilities, and capital-market access should fund U.S. requirements for the foreseeable future.
- Capital expenditures for the rest of 2014 were expected to be comparable to prior years as a percentage of sales. The filing gives no specific full-year revenue or earnings guidance.
- Risks highlighted include economic and geopolitical disruption, acquisition execution and integration, indebtedness and interest rates, foreign exchange, cyclical markets, customer concentration, raw-material costs, regulation, product liability and warranties, competition, and impairment of substantial goodwill and intangible assets.
- Ordinary-course legal claims include product-liability and employment matters; management believed provisions and insurance were adequate and did not expect a material adverse effect. Asbestos claims were also disclosed; potential liability could not be determined, and the company said it intended to defend claims vigorously.
- Goodwill and other intangible assets remained substantial; management reported no events requiring an interim impairment review. Disclosure controls were assessed as effective, with no material change to internal control over financial reporting reported.
Important facts for investors to verify
- Whether organic growth, orders, and backlog continue to support sales growth after accounting for acquisition contributions.
- Whether the expected 31% tax rate and the quarter’s tax benefits are reflected appropriately in forward earnings estimates.
- Debt-reduction progress, revolving-facility usage, covenant headroom, and the availability of $386 million held at foreign subsidiaries, which Roper considered permanently reinvested.
- Medical & Scientific Imaging’s acquisition-related contribution and margin performance, and integration costs in Energy Systems & Controls.
- Potential exposure from asbestos and other legal claims, warranty accruals, and any future goodwill or intangible-asset impairment indicators.